Document:

EX-10.21(i)

 Exhibit 10.21(i) 
  

 
 Re: Bridge Loan Agreement 

April 15, 2015 
 This Bridge Agreement (this
“Agreement”) is entered into effect on April 15, 2015 (the “Effective Date”), by and between Protagenic Therapeutics Inc, Inc., a Delaware corporation (the “Company”), and Dr. Garo H. Armen (the
“Lender”). 
 WHEREAS, the Lender, pursuant to the terms and conditions of this Agreement, will lend the Company an aggregate amount of twenty
thousand five hundred Dollars (US$ 20,700) (the “Loan Amount”). The loan (the “Loan”) shall be convertible into securities of the Company on the terms and conditions set forth herein. This loan will bear interest rate of 10% (ten
percent) per annum. 
 Protagenic Therapeutics agrees to guarantee the payment of all principal and accrued interest in the form of shares of its Common
Stock, $0.001 par value (“Common Stock”.) at a purchase price of $1.25 per share (“the Shares”) upon competing its next fundraising round. 

The proceeds will be used to fund the research and development and some operational activities for Protagenic Therapeutics Inc. 

The Lender will lend the Company the Loan Amount in one installment upon signature of the agreement. 

This Agreement will be governed by and construed in accordance with the laws of the State of New York, U.S.A., without regard to any choice of law principle
that would dictate the application of the law of another jurisdiction. The parties agree that any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be
commenced only in a court of the State of New York (or, if appropriate, a federal court located within the State of New York), and each party consents to the jurisdiction of such court. 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be considered one and the same
agreement. 
 IN WITNESS WHEREOF, duly authorized representatives of the parties have executed this Agreement as of the Effective Date. 

 

							
	 Dr. Garo H Armen
  

Print Name:

    Garo H. Armen
  

Signature:

    /s/ Garo H. Armen
	 		 		 	 PROTAGENIC THERAPEUTICS, INC.
 By: Dr.
Robert Ziroyan
  
 Print Name:

    Robert Ziroyan
  

Signature:

    /s/ Robert Ziroyan
  

Title: Chief Operating Officer and Interim President

 Protagenic Therapeutics Inc., 149 5th Avenue, Suite 500, New York, NY 10010 

Tel: 416-500-3305; Fax: 508.734.2177, www.protagenic.comEX-10.21(ii)

 Exhibit 10.21(ii) 
  

 
 Re: Bridge Loan Agreement 

May 28, 2015 
 This Bridge Agreement (this
“Agreement”) is entered into effect on May 28, 2015 (the “Effective Date”), by and between Protagenic Therapeutics Inc, Inc., a Delaware corporation (the “Company”), and Dr. Garo H. Armen (the
“Lender”). 
 WHEREAS, the Lender, pursuant to the terms and conditions of this Agreement, will lend the Company an aggregate amount of twenty
nine thousand five hundred Dollars (US$ 29,500) (the “Loan Amount”). The loan (the “Loan”) shall be convertible into securities of the Company on the terms and conditions set forth herein. This loan will bear interest rate of 10%
(ten percent) per annum. 
 Protagenic Therapeutics agrees to guarantee the payment of all principal and accrued interest in the form of shares of its
Common Stock, $0.001 par value (“Common Stock”.) at a purchase price of $1.25 per share (“the Shares”) upon competing its next fundraising round. 

The proceeds will be used to fund the research and development and some operational activities for Protagenic Therapeutics Inc. 

The Lender will lend the Company the Loan Amount in one installment upon signature of the agreement. 

This Agreement will be governed by and construed in accordance with the laws of the State of New York, U.S.A., without regard to any choice of law principle
that would dictate the application of the law of another jurisdiction. The parties agree that any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be
commenced only in a court of the State of New York (or, if appropriate, a federal court located within the State of New York), and each party consents to the jurisdiction of such court. 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be considered one and the same
agreement. 
 IN WITNESS WHEREOF, duly authorized representatives of the parties have executed this Agreement as of the Effective Date. 

 

							
	 Dr. Garo H Armen
  

Print Name:

    Garo H. Armen
  

Signature:

    /s/ Garo H. Armen
	 		 		 	 PROTAGENIC THERAPEUTICS, INC.
 By: Dr.
Robert Ziroyan
  
 Print Name:

    Robert Ziroyan
  

Signature:

    /s/ Robert Ziroyan
  

Title: Chief Operating Officer and Interim President

 Protagenic Therapeutics Inc., 149 5th Avenue, Suite 500, New York, NY 10010 

Tel: 416-500-3305; Fax: 508.734.2177, www.protagenic.comEX-10.21(iii)

 Exhibit 10.21(iii) 

 
 

 
 Re: Bridge Loan Agreement 

July 1, 2015 
 This Bridge Agreement (this
“Agreement”) is entered into effect on July 1, 2015 (the “Effective Date”), by and between Protagenic Therapeutics Inc, Inc., a Delaware corporation (the “Company”), and Dr. Garo H. Armen (the
“Lender”). 
 WHEREAS, the Lender, pursuant to the terms and conditions of this Agreement, will lend the Company an aggregate amount of seventy
four thousand four hundred ninety nine Dollars (US$ 74,499) (the “Loan Amount”). The loan (the “Loan”) shall be convertible into securities of the Company on the terms and conditions set forth herein. This loan will bear interest
rate of 10% (ten percent) per annum. 
 Protagenic Therapeutics agrees to guarantee the payment of all principal and accrued interest in the form of shares
of its Common Stock, $0.001 par value (“Common Stock”.) at a purchase price of $1.25 per share (“the Shares”) upon competing its next fundraising round. 

The proceeds will be used to fund the research and development and some operational activities for Protagenic Therapeutics Inc. 

The Lender will lend the Company the Loan Amount in two installments: (a) $29,200 upon signature of the agreement and b) $45,299 on August 25, 2015.

 This Agreement will be governed by and construed in accordance with the laws of the State of New York, U.S.A., without regard to any choice of law
principle that would dictate the application of the law of another jurisdiction. The parties agree that any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement
shall be commenced only in a court of the State of New York (or, if appropriate, a federal court located within the State of New York), and each party consents to the jurisdiction of such court. 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be considered one and the same
agreement. 
 IN WITNESS WHEREOF, duly authorized representatives of the parties have executed this Agreement as of the Effective Date. 

 

							
	 Dr. Garo H Armen
  

Print Name:

    Garo H. Armen
  

Signature:

    /s/ Garo H. Armen
	 		 		 	 PROTAGENIC THERAPEUTICS, INC.
 By: Dr.
Robert Ziroyan
  
 Print Name:

    Robert Ziroyan
  

Signature:

    /s/ Robert Ziroyan
  

Title: Chief Operating Officer and Interim President

 Protagenic Therapeutics Inc., 149 5th Avenue, Suite 500, New York, NY 10010 

Tel: 416-500-3305; Fax: 508.734.2177, www.protagenic.comEX-10.21(iv)

 Exhibit 10.21(iv) 
  

 
 Re: Bridge Loan Agreement 

September 1, 2015 
 This Bridge Agreement
(this “Agreement”) is entered into effect on September 1, 2015 (the “Effective Date”), by and between Protagenic Therapeutics Inc, Inc., a Delaware corporation (the “Company”), and Dr. Garo H. Armen (the
“Lender”). 
 WHEREAS, the Lender, pursuant to the terms and conditions of this Agreement, will lend the Company an aggregate amount of one
hundred thirty five thousand and three hundred one Dollars (US$ 135,301) (the “Loan Amount”). The loan (the “Loan”) shall be convertible into securities of the Company on the terms and conditions set forth herein. This loan will
bear interest rate of 10% (ten percent) per annum. 
 Protagenic Therapeutics agrees to guarantee the payment of all principal and accrued interest in the
form of shares of its Common Stock, $0.001 par value (“Common Stock”.) at a purchase price of $1.25 per share (“the Shares”) upon competing its next fundraising round. 

The proceeds will be used to fund the research and development and some operational activities for Protagenic Therapeutics Inc. 

The Lender will lend the Company the Loan Amount in three installments: (a) $25,000 upon signature of the agreement, (b) $64,450 on Sep 18, 2015 and
(c) $45,851 on Oct. 13, 2015. 
 This Agreement will be governed by and construed in accordance with the laws of the State of New York, U.S.A., without
regard to any choice of law principle that would dictate the application of the law of another jurisdiction. The parties agree that any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any
provision of this Agreement shall be commenced only in a court of the State of New York (or, if appropriate, a federal court located within the State of New York), and each party consents to the jurisdiction of such court. 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be considered one and the same
agreement. 
 IN WITNESS WHEREOF, duly authorized representatives of the parties have executed this Agreement as of the Effective Date. 

 

							
	 Dr. Garo H Armen
  

Print Name:

    Garo H. Armen
  

Signature:

    /s/ Garo H. Armen
	 		 		 	 PROTAGENIC THERAPEUTICS, INC.
 By: Dr.
Robert Ziroyan
  
 Print Name:

    Robert Ziroyan
  

Signature:

    /s/ Robert Ziroyan
  

Title: Chief Operating Officer and Interim President

 Protagenic Therapeutics Inc., 149 5th Avenue, Suite 500, New York, NY 10010 

Tel: 416-500-3305; Fax: 508.734.2177, www.protagenic.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]